{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:33:56Z","timestamp":1790775236210,"version":"4.1.0"},"reference-count":263,"publisher":"Georg Thieme Verlag KG","issue":"01","funder":[{"DOI":"10.13039\/501100001807","name":"S\u00e3o Paulo Research Foundation","doi-asserted-by":"crossref","award":["#2022\/02175-1"],"award-info":[{"award-number":["#2022\/02175-1"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"crossref","award":["R01 DK128289"],"award-info":[{"award-number":["R01 DK128289"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Primary liver cancer, or hepatocellular carcinoma (HCC), typically emerges in fibrotic livers where persistent inflammation and extracellular matrix (ECM) remodeling create a permissive niche for malignant transformation. Although cirrhosis remains a major risk factor, mounting data show that fibrosis itself, often in the context of metabolic dysfunction-associated steatotic liver disease (MASLD), can promote hepatocarcinogenesis even before cirrhosis develops. This review synthesizes mechanistic insights from hepatic stellate cell (HSC) biology and tumor immunology that position fibrosis as an instigator of HCC. Fibrotic remodeling increases ECM stiffness, distorts sinusoidal architecture, and promotes abnormal angiogenesis, while HSCs reprogram immune surveillance toward immune cell exclusion and immunosuppression. Aging and cellular senescence amplify these effects through a senescence-associated secretory phenotype in HSCs and hepatocytes, which fuels chronic inflammation and immune dysfunction. Metabolic crosstalk and extracellular vesicle exchange further couple stromal and epithelial programs, reinforcing stemness, therapy resistance, and metastatic fitness. In conclusion, the convergence of fibrogenic and oncogenic signaling drives HCC, uncovering actionable targets for its prevention and treatment.<\/jats:p>","DOI":"10.1055\/a-2779-4937","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:58:33Z","timestamp":1767139113000},"page":"031-050","source":"Crossref","is-referenced-by-count":8,"title":["Hepatic Fibrosis and Liver Cancer"],"prefix":"10.1055","volume":"46","author":[{"given":"Aina","family":"Anton","sequence":"additional","affiliation":[{"name":"Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Cl\u00ednic Barcelona, Fundaci\u00f3 de Recerca Cl\u00ednic Barcelona-Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Centro de Investigaci\u00f3n Biom\u00e9dica Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD), Barcelona, Spain"},{"name":"Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott L.","family":"Friedman","sequence":"additional","affiliation":[{"name":"Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, United States"},{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States"},{"name":"Mount Sinai Institute for Liver Research, Icahn School of Medicine at Mount Sinai, New York, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Cogliati","sequence":"additional","affiliation":[{"name":"Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, United States"},{"name":"Department of Pathology, School of Veterinary Medicine and Animal Science, University of S\u00e3o Paulo, S\u00e3o Paulo, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1186\/s12889-025-22026-6","article-title":"Global, regional and national burden of liver cancer 1990-2021: a systematic analysis of the global burden of disease study 2021","volume":"25","author":"Z Jiang","year":"2025","journal-title":"BMC Public Health"},{"issue":"03","key":"ref2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"F Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"28131","DOI":"10.1038\/s41598-024-77658-2","article-title":"Projected epidemiological trends and burden of liver cancer by 2040 based on GBD, CI5plus, and WHO data","volume":"14","author":"Q Guo","year":"2024","journal-title":"Sci Rep"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"e2445525","DOI":"10.1001\/jamanetworkopen.2024.45525","article-title":"Trends in hepatocellular carcinoma mortality rates in the US and projections through 2040","volume":"7","author":"S Qiu","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis\u2014aetiology, trends and predictions","volume":"20","author":"D Q Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref6","first-page":"1","article-title":"Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification","volume":"149","author":"S Chidambaranathan-Reghupaty","year":"2021","journal-title":"Adv Cancer Res"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","article-title":"Global epidemiology and genetics of hepatocellular carcinoma","volume":"164","author":"M R Toh","year":"2023","journal-title":"Gastroenterology"},{"issue":"09","key":"ref8","doi-asserted-by":"crossref","first-page":"101170","DOI":"10.1016\/j.xcrm.2023.101170","article-title":"The extracellular matrix in hepatocellular carcinoma: mechanisms and therapeutic vulnerability","volume":"4","author":"A M Roy","year":"2023","journal-title":"Cell Rep Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev-pathol-052016-100322","article-title":"The role of cancer-associated fibroblasts and fibrosis in liver cancer","volume":"12","author":"S Affo","year":"2017","journal-title":"Annu Rev Pathol"},{"issue":"03","key":"ref10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1055\/s-0039-1685539","article-title":"Contributions of fibroblasts, extracellular matrix, stiffness, and mechanosensing to hepatocarcinogenesis","volume":"39","author":"A Filliol","year":"2019","journal-title":"Semin Liver Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"111556","DOI":"10.1016\/j.fct.2020.111556","article-title":"The liver fibrosis niche: novel insights into the interplay between fibrosis-composing mesenchymal cells, immune cells, endothelial cells, and extracellular matrix","volume":"143","author":"M Matsuda","year":"2020","journal-title":"Food Chem Toxicol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1277808","DOI":"10.3389\/fimmu.2023.1277808","article-title":"Macrophages and platelets in liver fibrosis and hepatocellular carcinoma","volume":"14","author":"M Casari","year":"2023","journal-title":"Front Immunol"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-0040-1708876","article-title":"Hepatic stellate cell-macrophage crosstalk in liver fibrosis and carcinogenesis","volume":"40","author":"M Matsuda","year":"2020","journal-title":"Semin Liver Dis"},{"issue":"07","key":"ref14","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3390\/ijms20071723","article-title":"The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma","volume":"20","author":"J Baglieri","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"18","key":"ref15","doi-asserted-by":"crossref","first-page":"10777","DOI":"10.3390\/ijms231810777","article-title":"Hepatic stellate cell modulates the immune microenvironment in the progression of hepatocellular carcinoma","volume":"23","author":"P W Wang","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"05","key":"ref16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/jcag\/gwae025","article-title":"Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies","volume":"7","author":"F Jaber","year":"2024","journal-title":"J Can Assoc Gastroenterol"},{"issue":"16","key":"ref17","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.3390\/jcm13164657","article-title":"MASLD-related hepatocarcinoma: special features and challenges","volume":"13","author":"C Yag\u00fce-Caballero","year":"2024","journal-title":"J Clin Med"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"e16125","DOI":"10.1111\/liv.16125","article-title":"Spatial and single-cell transcriptomics reveals the regional division of the spatial structure of MASH fibrosis","volume":"45","author":"J Z Li","year":"2025","journal-title":"Liver Int"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.jhep.2020.06.004","article-title":"Single-cell genomics and spatial transcriptomics: discovery of novel cell states and cellular interactions in liver physiology and disease biology","volume":"73","author":"A Saviano","year":"2020","journal-title":"J Hepatol"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41467-024-55325-4","article-title":"Spatial transcriptomics of healthy and fibrotic human liver at single-cell resolution","volume":"16","author":"B R Watson","year":"2025","journal-title":"Nat Commun"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1574385","DOI":"10.3389\/fphar.2025.1574385","article-title":"Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective","volume":"16","author":"X Zeng","year":"2025","journal-title":"Front Pharmacol"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/HEP.0000000000000182","article-title":"Hepatic fibrosis: targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines","volume":"78","author":"L Gong","year":"2023","journal-title":"Hepatology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"11808","DOI":"10.3389\/jpps.2023.11808","article-title":"Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches","volume":"26","author":"O S Mohammed","year":"2023","journal-title":"J Pharm Pharm Sci"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1582258","DOI":"10.3389\/fphar.2025.1582258","article-title":"Research and application of medicines for treating liver fibrosis: current status and prospects","volume":"16","author":"S Chen","year":"2025","journal-title":"Front Pharmacol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"874408","DOI":"10.3389\/fphar.2022.874408","article-title":"New drugs for hepatic fibrosis","volume":"13","author":"L Shan","year":"2022","journal-title":"Front Pharmacol"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ymthe.2022.09.012","article-title":"Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma","volume":"31","author":"X Liu","year":"2023","journal-title":"Mol Ther"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.canlet.2021.05.007","article-title":"Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation","volume":"513","author":"M Y Ke","year":"2021","journal-title":"Cancer Lett"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1369\/00221554211056853","article-title":"Current perspectives on the immunosuppressive niche and role of fibrosis in hepatocellular carcinoma and the development of antitumor immunity","volume":"70","author":"T Aoki","year":"2022","journal-title":"J Histochem Cytochem"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s43556-024-00184-0","article-title":"Signaling pathways in liver cancer: pathogenesis and targeted therapy","volume":"5","author":"Y Xue","year":"2024","journal-title":"Mol Biomed"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.hbpd.2022.10.003","article-title":"Wnt\/beta-catenin signaling and its modulators in nonalcoholic fatty liver diseases","volume":"22","author":"K Shree Harini","year":"2023","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10565-024-09956-4","article-title":"Investigating the role of Wnt3a and Wnt5a as critical factors of hepatic stellate cell activation in acute toxicant-induced liver injury","volume":"41","author":"L N Rutt","year":"2024","journal-title":"Cell Biol Toxicol"},{"issue":"06","key":"ref32","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.3892\/mmr.2014.2099","article-title":"\u03b2-catenin is overexpressed in hepatic fibrosis and blockage of Wnt\/\u03b2-catenin signaling inhibits hepatic stellate cell activation","volume":"9","author":"W S Ge","year":"2014","journal-title":"Mol Med Rep"},{"issue":"10","key":"ref33","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1002\/hep4.2043","article-title":"Inhibition of CBP\/\u03b2-catenin signaling ameliorated fibrosis in cholestatic liver disease","volume":"6","author":"M Kimura","year":"2022","journal-title":"Hepatol Commun"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"G39","DOI":"10.1152\/ajpgi.00263.2007","article-title":"Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis","volume":"294","author":"J H Cheng","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"06","key":"ref35","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/ng.2256","article-title":"Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma","volume":"44","author":"C Guichard","year":"2012","journal-title":"Nat Genet"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1038\/s41416-024-02849-7","article-title":"Specific features of \u03b2-catenin-mutated hepatocellular carcinomas","volume":"131","author":"C Dantzer","year":"2024","journal-title":"Br J Cancer"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"101186","DOI":"10.1016\/j.jhepr.2024.101186","article-title":"Development of mutated \u03b2-catenin gene signature to identify CTNNB1 mutations from whole and spatial transcriptomic data in patients with HCC","volume":"6","author":"B M Lehrich","year":"2024","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s44324-025-00063-4","article-title":"ECM formation and degradation during fibrosis, repair, and regeneration","volume":"3","author":"A E Mayorca-Guiliani","year":"2025","journal-title":"NPJ Metab Health Dis"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.31236","article-title":"Lysyl oxidase (LOX) family members: rationale and their potential as therapeutic targets for liver fibrosis","volume":"72","author":"W Chen","year":"2020","journal-title":"Hepatology"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1098129","DOI":"10.3389\/fphys.2023.1098129","article-title":"Regulators, functions, and mechanotransduction pathways of matrix stiffness in hepatic disease","volume":"14","author":"T Guo","year":"2023","journal-title":"Front Physiol"},{"issue":"08","key":"ref41","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/carcin\/bgac035","article-title":"Liver tumor-initiating cells initiate the formation of a stiff cancer stem cell microenvironment niche by secreting LOX","volume":"43","author":"W Zhao","year":"2022","journal-title":"Carcinogenesis"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12915-025-02113-1","article-title":"High matrix stiffness accelerates migration of hepatocellular carcinoma cells through the integrin \u03b21-Plectin-F-actin axis","volume":"23","author":"Z Wang","year":"2025","journal-title":"BMC Biol"},{"issue":"04","key":"ref43","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3390\/cancers14041049","article-title":"Matrix stiffness contributes to cancer progression by regulating transcription factors","volume":"14","author":"S Ishihara","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.3390\/ijms19113674","article-title":"YAP\/TAZ signaling as a molecular link between fibrosis and cancer","volume":"19","author":"S Noguchi","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"06","key":"ref45","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1097\/HEP.0000000000000326","article-title":"Targeting YAP-mediated HSC death susceptibility and senescence for treatment of liver fibrosis","volume":"77","author":"K Du","year":"2023","journal-title":"Hepatology"},{"issue":"422","key":"ref46","doi-asserted-by":"crossref","first-page":"eaao0475","DOI":"10.1126\/scitranslmed.aao0475","article-title":"Targeting extracellular matrix stiffness to attenuate disease: from molecular mechanisms to clinical trials","volume":"10","author":"M C Lampi","year":"2018","journal-title":"Sci Transl Med"},{"issue":"12","key":"ref47","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.7150\/ijbs.37500","article-title":"Matrix mechanics as regulatory factors and therapeutic targets in hepatic fibrosis","volume":"15","author":"G Chen","year":"2019","journal-title":"Int J Biol Sci"},{"issue":"11","key":"ref48","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1016\/j.bpj.2016.04.040","article-title":"A computational model of YAP\/TAZ mechanosensing","volume":"110","author":"M Sun","year":"2016","journal-title":"Biophys J"},{"issue":"7350","key":"ref49","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10137","article-title":"Role of YAP\/TAZ in mechanotransduction","volume":"474","author":"S Dupont","year":"2011","journal-title":"Nature"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41419-021-04418-9","article-title":"Matrix stiffness modulates hepatic stellate cell activation into tumor-promoting myofibroblasts via E2F3-dependent signaling and regulates malignant progression","volume":"12","author":"Z Liu","year":"2021","journal-title":"Cell Death Dis"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3892\/ijo.2024.5676","article-title":"Targeting the Hippo\/YAP1 signaling pathway in hepatocellular carcinoma: from mechanisms to therapeutic drugs (Review)","volume":"65","author":"S Li","year":"2024","journal-title":"Int J Oncol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1377722","DOI":"10.3389\/fimmu.2024.1377722","article-title":"Targeting YAP1 to improve the efficacy of immune checkpoint inhibitors in liver cancer: mechanism and strategy","volume":"15","author":"Y Gao","year":"2024","journal-title":"Front Immunol"},{"issue":"05","key":"ref53","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2014.06.033","article-title":"YAP activation is an early event and a potential therapeutic target in liver cancer development","volume":"61","author":"A Perra","year":"2014","journal-title":"J Hepatol"},{"issue":"05","key":"ref54","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3390\/ph17050644","article-title":"Extracellular matrix stiffness-induced mechanotransduction of capillarized liver sinusoidal endothelial cells","volume":"17","author":"Q Wu","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"01","key":"ref55","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","article-title":"Liver sinusoidal endothelial cells: physiology and role in liver diseases","volume":"66","author":"J Poisson","year":"2017","journal-title":"J Hepatol"},{"issue":"21","key":"ref56","doi-asserted-by":"crossref","first-page":"12066","DOI":"10.3390\/ijms222112066","article-title":"Substrate stiffness drives epithelial to mesenchymal transition and proliferation through the NEAT1-Wnt\/\u03b2-catenin pathway in liver cancer","volume":"22","author":"X Xu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"213936","DOI":"10.1016\/j.bioadv.2024.213936","article-title":"Matrix stiffening facilitates stemness of liver cancer stem cells by YAP activation and BMF inhibition","volume":"163","author":"D Ma","year":"2024","journal-title":"Biomater Adv"},{"issue":"08","key":"ref58","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41401-024-01261-4","article-title":"Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma","volume":"45","author":"Q Y Zhang","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"18272","DOI":"10.1038\/srep18272","article-title":"The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis","volume":"5","author":"R Bansal","year":"2015","journal-title":"Sci Rep"},{"issue":"06","key":"ref60","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00018-022-04319-w","article-title":"Macrophages evoke autophagy of hepatic stellate cells to promote liver fibrosis in NAFLD mice via the PGE2\/EP4 pathway","volume":"79","author":"Y Cao","year":"2022","journal-title":"Cell Mol Life Sci"},{"issue":"11","key":"ref61","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.molmed.2019.06.007","article-title":"Immunomodulatory TGF-\u03b2 signaling in hepatocellular carcinoma","volume":"25","author":"J Chen","year":"2019","journal-title":"Trends Mol Med"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3389\/fonc.2018.00357","article-title":"Transforming growth factor-\u03b2-induced cell plasticity in liver fibrosis and hepatocarcinogenesis","volume":"8","author":"I Fabregat","year":"2018","journal-title":"Front Oncol"},{"issue":"32","key":"ref63","doi-asserted-by":"crossref","first-page":"52294","DOI":"10.18632\/oncotarget.10561","article-title":"TGF-\u03b2 induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype","volume":"7","author":"F Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"39","key":"ref64","doi-asserted-by":"crossref","first-page":"14308","DOI":"10.1074\/jbc.RA119.007674","article-title":"A hierarchical network of hypoxia-inducible factor and SMAD proteins governs procollagen lysyl hydroxylase 2 induction by hypoxia and transforming growth factor \u03b21","volume":"294","author":"T Rosell-Garc\u00eda","year":"2019","journal-title":"J Biol Chem"},{"issue":"01","key":"ref65","doi-asserted-by":"crossref","first-page":"18840","DOI":"10.1038\/s41598-024-69898-z","article-title":"Hepatic stellate cells in zone 1 engage in capillarization rather than myofibroblast formation in murine liver fibrosis","volume":"14","author":"M A Khan","year":"2024","journal-title":"Sci Rep"},{"issue":"29","key":"ref66","doi-asserted-by":"crossref","first-page":"110114","DOI":"10.3748\/wjg.v31.i29.110114","article-title":"Targeting tumor vascular endothelial cells for hepatocellular carcinoma treatment","volume":"31","author":"C Y Zhang","year":"2025","journal-title":"World J Gastroenterol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1196298","DOI":"10.3389\/fonc.2023.1196298","article-title":"New insights into fibrotic signaling in hepatocellular carcinoma","volume":"13","author":"L Shan","year":"2023","journal-title":"Front Oncol"},{"issue":"03","key":"ref68","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3350\/cmh.2024.0022","article-title":"Liver sinusoidal endothelial cell: an important yet often overlooked player in the liver fibrosis","volume":"30","author":"J Qu","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"03","key":"ref69","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2024.05.014","article-title":"Angiocrine signaling in sinusoidal homeostasis and liver diseases","volume":"81","author":"J Gao","year":"2024","journal-title":"J Hepatol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1497788","DOI":"10.3389\/fimmu.2024.1497788","article-title":"Liver sinusoidal endothelial cells regulate the balance between hepatic immunosuppression and immunosurveillance","volume":"15","author":"K N Kremer","year":"2025","journal-title":"Front Immunol"},{"issue":"01","key":"ref71","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13045-024-01527-8","article-title":"Metabolic reprogramming in the tumor microenvironment of liver cancer","volume":"17","author":"J Lin","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"01","key":"ref72","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Z Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"08","key":"ref73","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1042\/CS20140823","article-title":"CD147 promotes liver fibrosis progression via VEGF-A\/VEGFR2 signalling-mediated cross-talk between hepatocytes and sinusoidal endothelial cells","volume":"129","author":"Z Yan","year":"2015","journal-title":"Clin Sci (Lond)"},{"issue":"02","key":"ref74","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/HEP.0000000000000207","article-title":"The evolving role of liver sinusoidal endothelial cells in liver health and disease","volume":"78","author":"M J McConnell","year":"2023","journal-title":"Hepatology"},{"issue":"01","key":"ref75","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3350\/cmh.2024.0734","article-title":"Sinusoidal communication in chronic liver disease","volume":"31","author":"A Gibert-Ramos","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"01","key":"ref76","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12967-021-02854-x","article-title":"The roles and mechanisms of hypoxia in liver fibrosis","volume":"19","author":"J Cai","year":"2021","journal-title":"J Transl Med"},{"issue":"07","key":"ref77","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3390\/cells10071764","article-title":"Hypoxia, hypoxia-inducible factors and liver fibrosis","volume":"10","author":"B Foglia","year":"2021","journal-title":"Cells"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"1129831","DOI":"10.3389\/fmolb.2023.1129831","article-title":"The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancer\u2014challenges and opportunities","volume":"10","author":"M S Kohlhepp","year":"2023","journal-title":"Front Mol Biosci"},{"issue":"03","key":"ref79","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.32299","article-title":"A strategy of vascular-targeted therapy for liver fibrosis","volume":"76","author":"Y Lin","year":"2022","journal-title":"Hepatology"},{"issue":"08","key":"ref80","doi-asserted-by":"crossref","first-page":"e73492","DOI":"10.1371\/journal.pone.0073492","article-title":"Bevacizumab attenuates hepatic fibrosis in rats by inhibiting activation of hepatic stellate cells","volume":"8","author":"Y Huang","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"ref81","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.3390\/ijms25115584","article-title":"The role of metabolic reprogramming in the tumor immune microenvironment: mechanisms and opportunities for immunotherapy in hepatocellular carcinoma","volume":"25","author":"N Hu","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"07","key":"ref82","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cmet.2024.05.003","article-title":"Metabolic reprogramming in liver fibrosis","volume":"36","author":"P Horn","year":"2024","journal-title":"Cell Metab"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"1243675","DOI":"10.3389\/fphar.2023.1243675","article-title":"Immunometabolism changes in fibrosis: from mechanisms to therapeutic strategies","volume":"14","author":"L Feng","year":"2023","journal-title":"Front Pharmacol"},{"issue":"S 03","key":"ref84","doi-asserted-by":"crossref","first-page":"S375","DOI":"10.1245\/s10434-011-1836-7","article-title":"The significance of MMP-9 over MMP-2 in HCC invasiveness and recurrence of hepatocellular carcinoma after curative resection","volume":"19","author":"R Chen","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"ref85","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41419-019-2101-4","article-title":"MKL1 promotes endothelial-to-mesenchymal transition and liver fibrosis by activating TWIST1 transcription","volume":"10","author":"Z Li","year":"2019","journal-title":"Cell Death Dis"},{"issue":"32","key":"ref86","doi-asserted-by":"crossref","first-page":"23337","DOI":"10.1074\/jbc.M700194200","article-title":"Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition","volume":"282","author":"M Zeisberg","year":"2007","journal-title":"J Biol Chem"},{"issue":"08","key":"ref87","first-page":"698","article-title":"Epithelial-to-mesenchymal transition: a mediator of sorafenib resistance in advanced hepatocellular carcinoma","volume":"17","author":"N Mir","year":"2017","journal-title":"Curr Cancer Drug Targets"},{"issue":"14","key":"ref88","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.3390\/ijms22147575","article-title":"TGF-\u03b2 signaling: from tissue fibrosis to tumor microenvironment","volume":"22","author":"J Y Chung","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"20","key":"ref89","doi-asserted-by":"crossref","first-page":"e70152","DOI":"10.1111\/jcmm.70152","article-title":"Single-cell and spatial transcriptomics reveal apelin\/APJ pathway's role in microvessel formation and tumour progression in hepatocellular carcinoma","volume":"28","author":"Y Zhu","year":"2024","journal-title":"J Cell Mol Med"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"6970407","DOI":"10.1155\/2018\/6970407","article-title":"PPAR\u03b3 antagonizes hypoxia-induced activation of hepatic stellate cell through cross mediating PI3K\/AKT and cGMP\/PKG signaling","volume":"2018","author":"Q Zhang","year":"2018","journal-title":"PPAR Res"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.biochi.2019.04.006","article-title":"Long non-coding RNA H19, a negative regulator of microRNA-148b-3p, participates in hypoxia stress in human hepatic sinusoidal endothelial cells via NOX4 and eNOS\/NO signaling","volume":"163","author":"Y Zhu","year":"2019","journal-title":"Biochimie"},{"issue":"04","key":"ref92","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3390\/livers1040021","article-title":"Noncoding RNAs interactions in hepatic stellate cells during hepatic fibrosis","volume":"1","author":"S A Sulaiman","year":"2021","journal-title":"Livers"},{"issue":"01","key":"ref93","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s13046-018-0965-2","article-title":"Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts","volume":"37","author":"Y Zhou","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"ref94","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ajpath.2022.06.007","article-title":"The role of extracellular vesicles in liver pathogenesis","volume":"192","author":"G Liu","year":"2022","journal-title":"Am J Pathol"},{"issue":"12","key":"ref95","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1136\/gutjnl-2013-306294","article-title":"CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis","volume":"63","author":"J Ehling","year":"2014","journal-title":"Gut"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.canlet.2018.01.064","article-title":"Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2","volume":"420","author":"C J Qin","year":"2018","journal-title":"Cancer Lett"},{"issue":"02","key":"ref97","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/1440-1681.12689","article-title":"A tumour-promoting role of Th9 cells in hepatocellular carcinoma through CCL20 and STAT3 pathways","volume":"44","author":"H Tan","year":"2017","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"02","key":"ref98","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.canlet.2014.11.044","article-title":"CXCR2\/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K\/Akt\/GSK-3\u03b2\/Snail signaling","volume":"358","author":"S L Zhou","year":"2015","journal-title":"Cancer Lett"},{"issue":"01","key":"ref99","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"J M Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"18","key":"ref100","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"O E Rahma","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"08","key":"ref101","doi-asserted-by":"crossref","first-page":"djw030","DOI":"10.1093\/jnci\/djw030","article-title":"Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma","volume":"108","author":"E A Kuczynski","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"ref102","doi-asserted-by":"crossref","first-page":"109253","DOI":"10.1016\/j.celrep.2021.109253","article-title":"Tumor vessel co-option probed by single-cell analysis","volume":"35","author":"L A Teuwen","year":"2021","journal-title":"Cell Rep"},{"issue":"07","key":"ref103","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/hep4.1716","article-title":"Characteristics and prognosis of de novo hepatocellular carcinoma after sustained virologic response","volume":"5","author":"H Toyoda","year":"2021","journal-title":"Hepatol Commun"},{"issue":"06","key":"ref104","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.cgh.2018.10.038","article-title":"Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection","volume":"17","author":"E Degasperi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"ref105","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","article-title":"Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy","volume":"55","author":"Y Choi","year":"2023","journal-title":"Exp Mol Med"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"1291530","DOI":"10.3389\/fimmu.2023.1291530","article-title":"Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy","volume":"14","author":"C Qian","year":"2023","journal-title":"Front Immunol"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"1386772","DOI":"10.3389\/fonc.2024.1386772","article-title":"Vessel co-option: a unique vascular-immune niche in liver cancer","volume":"14","author":"D Yang","year":"2024","journal-title":"Front Oncol"},{"issue":"08","key":"ref108","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1111\/jcmm.16363","article-title":"Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis","volume":"25","author":"H Ogawa","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"01","key":"ref109","first-page":"257","article-title":"Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo","volume":"58","author":"F Hong","year":"2013","journal-title":"Dig Dis Sci"},{"issue":"01","key":"ref110","doi-asserted-by":"crossref","first-page":"e13158","DOI":"10.1111\/cpr.13158","article-title":"Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF-1\u03b1\/SLC7A11 pathway","volume":"55","author":"S Yuan","year":"2022","journal-title":"Cell Prolif"},{"issue":"12","key":"ref111","first-page":"e1318","article-title":"Vascular co-option and vasculogenic mimicry mediate resistance to antiangiogenic strategies","volume":"5","author":"F Pezzella","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"issue":"03","key":"ref112","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41416-021-01330-z","article-title":"Vascular normalisation as the stepping stone into tumour microenvironment transformation","volume":"125","author":"A L Magnussen","year":"2021","journal-title":"Br J Cancer"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"929141","DOI":"10.3389\/fimmu.2022.929141","article-title":"Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma","volume":"13","author":"Y Xin","year":"2022","journal-title":"Front Immunol"},{"issue":"02","key":"ref114","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3390\/cancers15020348","article-title":"Unraveling the synergy between atezolizumab and bevacizumab for the treatment of hepatocellular carcinoma","volume":"15","author":"C Brackenier","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"1533033819879905","DOI":"10.1177\/1533033819879905","article-title":"Cancer-associated fibroblasts promote angiogenesis of hepatocellular carcinoma by VEGF-mediated EZH2\/VASH1 pathway","volume":"18","author":"B Huang","year":"2019","journal-title":"Technol Cancer Res Treat"},{"issue":"03","key":"ref116","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jhep.2008.12.011","article-title":"Angiogenesis in liver disease","volume":"50","author":"M Fern\u00e1ndez","year":"2009","journal-title":"J Hepatol"},{"issue":"20","key":"ref117","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"R S Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"05","key":"ref118","doi-asserted-by":"crossref","first-page":"e1247","DOI":"10.1002\/ctm2.1247","article-title":"BMP9-induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus-associated hepatocellular carcinoma","volume":"13","author":"Y Han","year":"2023","journal-title":"Clin Transl Med"},{"issue":"01","key":"ref119","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13020-024-01038-1","article-title":"Si-Wu-Tang improves liver fibrosis by restoring liver sinusoidal endothelial cell functionality and reducing communication with hepatic stellate cells","volume":"19","author":"L Wang","year":"2024","journal-title":"Chin Med"},{"issue":"01","key":"ref120","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12964-024-01720-9","article-title":"Role of liver sinusoidal endothelial cell in metabolic dysfunction-associated fatty liver disease","volume":"22","author":"Q He","year":"2024","journal-title":"Cell Commun Signal"},{"issue":"03","key":"ref121","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"M Ringelhan","year":"2018","journal-title":"Nat Immunol"},{"issue":"7783","key":"ref122","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"P Ramachandran","year":"2019","journal-title":"Nature"},{"issue":"09","key":"ref123","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1002\/hep4.2001","article-title":"Spatial transcriptomics identifies enriched gene expression and cell types in human liver fibrosis","volume":"6","author":"B K Chung","year":"2022","journal-title":"Hepatol Commun"},{"issue":"04","key":"ref124","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","article-title":"Landscape and dynamics of single immune cells in hepatocellular carcinoma","volume":"179","author":"Q Zhang","year":"2019","journal-title":"Cell"},{"issue":"21","key":"ref125","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.3390\/cells11213387","article-title":"Multiplexed digital spatial protein profiling reveals distinct phenotypes of mononuclear phagocytes in livers with advanced fibrosis","volume":"11","author":"J Lee","year":"2022","journal-title":"Cells"},{"issue":"05","key":"ref126","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jhep.2022.06.004","article-title":"Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH","volume":"77","author":"T Hendrikx","year":"2022","journal-title":"J Hepatol"},{"issue":"01","key":"ref127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-024-00747-z","article-title":"Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma","volume":"11","author":"Y Cheng","year":"2025","journal-title":"Cell Discov"},{"issue":"01","key":"ref128","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12967-025-06192-0","article-title":"Integration of single-cell and spatial transcriptomics reveals fibroblast subtypes in hepatocellular carcinoma: spatial distribution, differentiation trajectories, and therapeutic potential","volume":"23","author":"Y Liu","year":"2025","journal-title":"J Transl Med"},{"issue":"07","key":"ref129","doi-asserted-by":"crossref","first-page":"e008721","DOI":"10.1136\/jitc-2023-008721","article-title":"POSTN+ cancer-associated fibroblasts determine the efficacy of immunotherapy in hepatocellular carcinoma","volume":"12","author":"H Wang","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"12","key":"ref130","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.7150\/thno.99046","article-title":"DAB2\n               + macrophages support FAP\n               + fibroblasts in shaping tumor barrier and inducing poor clinical outcomes in liver cancer","volume":"14","author":"F Long","year":"2024","journal-title":"Theranostics"},{"issue":"01","key":"ref131","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41421-023-00529-z","article-title":"CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor","volume":"9","author":"G Q Zhu","year":"2023","journal-title":"Cell Discov"},{"issue":"06","key":"ref132","doi-asserted-by":"crossref","first-page":"101330","DOI":"10.1016\/j.gendis.2024.101330","article-title":"Cancer-associated fibroblasts derived fibronectin extra domain A promotes sorafenib resistance in hepatocellular carcinoma cells by activating SHMT1","volume":"11","author":"Y Dong","year":"2024","journal-title":"Genes Dis"},{"issue":"06","key":"ref133","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/hep.30093","article-title":"High mobility group box-1 drives fibrosis progression signaling via the receptor for advanced glycation end products in mice","volume":"68","author":"X Ge","year":"2018","journal-title":"Hepatology"},{"issue":"11","key":"ref134","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-beta signaling and hepatic fibrosis","volume":"13","author":"E Seki","year":"2007","journal-title":"Nat Med"},{"issue":"01","key":"ref135","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1186\/s12885-023-11613-8","article-title":"Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12\/FOLR1","volume":"23","author":"J Zhao","year":"2023","journal-title":"BMC Cancer"},{"issue":"04","key":"ref136","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jcmgh.2023.01.006","article-title":"Cancer-associated fibroblasts in hepatocellular carcinoma and cholangiocarcinoma","volume":"15","author":"F Ying","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"01","key":"ref137","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40164-024-00539-x","article-title":"Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside","volume":"13","author":"Y Yin","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"01","key":"ref138","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s13046-023-02900-0","article-title":"Cancer-associated fibroblasts-derived CXCL12 enhances immune escape of bladder cancer through inhibiting P62-mediated autophagic degradation of PDL1","volume":"42","author":"Z Zhang","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"ref139","doi-asserted-by":"crossref","first-page":"1089068","DOI":"10.3389\/fcell.2023.1089068","article-title":"Cancer-associated fibroblasts: the chief architect in the tumor microenvironment","volume":"11","author":"M Sarkar","year":"2023","journal-title":"Front Cell Dev Biol"},{"issue":"02","key":"ref140","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.canlet.2011.12.020","article-title":"Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO","volume":"318","author":"T Li","year":"2012","journal-title":"Cancer Lett"},{"issue":"01","key":"ref141","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"X Mao","year":"2021","journal-title":"Mol Cancer"},{"issue":"14","key":"ref142","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1177\/15353702221092672","article-title":"The antifibrotic role of natural killer cells in liver fibrosis","volume":"247","author":"Y Wei","year":"2022","journal-title":"Exp Biol Med (Maywood)"},{"issue":"09","key":"ref143","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1111\/jgh.16584","article-title":"Immune signature and therapeutic approach of natural killer cell in chronic liver disease and hepatocellular carcinoma","volume":"39","author":"S K Shin","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"ref144","doi-asserted-by":"crossref","first-page":"111341","DOI":"10.1016\/j.intimp.2023.111341","article-title":"Interleukin-10 gene intervention ameliorates liver fibrosis by enhancing the immune function of natural killer cells in liver tissue","volume":"127","author":"Y Chen","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"ref145","doi-asserted-by":"crossref","first-page":"100883","DOI":"10.1016\/j.jhepr.2023.100883","article-title":"Single-cell landscape of immune cells in human livers affected by HBV-related cirrhosis","volume":"5","author":"Q Bai","year":"2023","journal-title":"JHEP Rep Innov Hepatol"},{"key":"ref146","doi-asserted-by":"crossref","first-page":"1137034","DOI":"10.3389\/fimmu.2023.1137034","article-title":"Etiology of end-stage liver cirrhosis impacts hepatic natural killer cell heterogenicity","volume":"14","author":"A C Maretti-Mira","year":"2023","journal-title":"Front Immunol"},{"issue":"08","key":"ref147","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/jgh.16564","article-title":"The role of tumor-associated macrophages in hepatocellular carcinoma-from bench to bedside: a review","volume":"39","author":"M Gryziak","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"ref148","first-page":"e0578","article-title":"Biological and clinical role of TREM2 in liver diseases","volume":"8","author":"K Ma","year":"2024","journal-title":"Hepatol Commun"},{"issue":"12","key":"ref149","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41423-024-01232-z","article-title":"Targeting of TAMs: can we be more clever than cancer cells?","volume":"21","author":"J Kzhyshkowska","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"ref150","doi-asserted-by":"crossref","first-page":"1171794","DOI":"10.3389\/fonc.2023.1171794","article-title":"Regulation of tumor angiogenesis by the crosstalk between innate immunity and endothelial cells","volume":"13","author":"S Ebeling","year":"2023","journal-title":"Front Oncol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1431211","DOI":"10.3389\/fimmu.2024.1431211","article-title":"Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy","volume":"15","author":"G Du","year":"2024","journal-title":"Front Immunol"},{"issue":"01","key":"ref152","doi-asserted-by":"crossref","first-page":"187","DOI":"10.37349\/etat.2024.00212","article-title":"Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment","volume":"5","author":"E Jou","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"issue":"03","key":"ref153","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3892\/ol.2022.13213","article-title":"Myeloid-derived suppressor cell infiltration is associated with a poor prognosis in patients with hepatocellular carcinoma","volume":"23","author":"T Tomiyama","year":"2022","journal-title":"Oncol Lett"},{"issue":"01","key":"ref154","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41389-022-00398-3","article-title":"Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy","volume":"11","author":"H Raskov","year":"2022","journal-title":"Oncogenesis"},{"issue":"04","key":"ref155","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.ymthe.2025.02.002","article-title":"Overcoming immunotherapy resistance in hepatocellular carcinoma by targeting myeloid IL-8\/CXCR2 signaling","volume":"33","author":"T T Kwong","year":"2025","journal-title":"Mol Ther"},{"key":"ref156","doi-asserted-by":"crossref","first-page":"29","DOI":"10.21037\/tgh-23-11","article-title":"Impact of immune tolerance mechanisms on the efficacy of immunotherapy in primary and secondary liver cancers","volume":"8","author":"K Sankar","year":"2023","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"05","key":"ref157","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"A Del Prete","year":"2023","journal-title":"Cell Mol Immunol"},{"issue":"06","key":"ref158","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","article-title":"Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma","volume":"29","author":"A Magen","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"ref159","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41423-025-01308-4","article-title":"Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy","volume":"22","author":"D Seyhan","year":"2025","journal-title":"Cell Mol Immunol"},{"issue":"01","key":"ref160","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41392-021-00784-0","article-title":"GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages","volume":"6","author":"J Chen","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"01","key":"ref161","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1186\/s12885-018-4435-1","article-title":"VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma","volume":"18","author":"M Zhang","year":"2018","journal-title":"BMC Cancer"},{"issue":"04","key":"ref162","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2023.12.015","article-title":"IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction","volume":"80","author":"A M Shiri","year":"2024","journal-title":"J Hepatol"},{"issue":"01","key":"ref163","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41420-024-01995-4","article-title":"IL-17a promotes hepatocellular carcinoma by increasing FAP expression in hepatic stellate cells via activation of the STAT3 signaling pathway","volume":"10","author":"D Sun","year":"2024","journal-title":"Cell Death Discov"},{"issue":"03","key":"ref164","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1053\/j.gastro.2012.05.049","article-title":"Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice","volume":"143","author":"F Meng","year":"2012","journal-title":"Gastroenterology"},{"issue":"72","key":"ref165","doi-asserted-by":"crossref","first-page":"eabl7209","DOI":"10.1126\/sciimmunol.abl7209","article-title":"Gasdermin D-mediated release of IL-33 from senescent hepatic stellate cells promotes obesity-associated hepatocellular carcinoma","volume":"7","author":"R Yamagishi","year":"2022","journal-title":"Sci Immunol"},{"issue":"01","key":"ref166","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1186\/s12967-024-05613-w","article-title":"Spatial transcriptomics reveals tumor-derived SPP1 induces fibroblast chemotaxis and activation in the hepatocellular carcinoma microenvironment","volume":"22","author":"W Tong","year":"2024","journal-title":"J Transl Med"},{"issue":"03","key":"ref167","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/HEP.0000000000000591","article-title":"Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma","volume":"79","author":"M Li","year":"2024","journal-title":"Hepatology"},{"issue":"01","key":"ref168","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s42003-020-01441-y","article-title":"Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy","volume":"3","author":"M M Tu","year":"2020","journal-title":"Commun Biol"},{"issue":"10","key":"ref169","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1136\/gutjnl-2021-326259","article-title":"CXCR2 inhibition enables NASH-HCC immunotherapy","volume":"71","author":"J Leslie","year":"2022","journal-title":"Gut"},{"issue":"60","key":"ref170","doi-asserted-by":"crossref","first-page":"101591","DOI":"10.18632\/oncotarget.21353","article-title":"Molecular characteristics of hepatocellular carcinomas from different age groups","volume":"8","author":"C Ang","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"ref171","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41574-018-0059-4","article-title":"Inflammaging: a new immune-metabolic viewpoint for age-related diseases","volume":"14","author":"C Franceschi","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"07","key":"ref172","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0968-0004(02)02110-2","article-title":"Oxidative stress shortens telomeres","volume":"27","author":"T von Zglinicki","year":"2002","journal-title":"Trends Biochem Sci"},{"issue":"06","key":"ref173","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"C L\u00f3pez-Ot\u00edn","year":"2013","journal-title":"Cell"},{"issue":"09","key":"ref174","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrm2233","article-title":"Cellular senescence: when bad things happen to good cells","volume":"8","author":"J Campisi","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref175","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: the dark side of tumor suppression","volume":"5","author":"J P Copp\u00e9","year":"2010","journal-title":"Annu Rev Pathol"},{"key":"ref176","doi-asserted-by":"crossref","first-page":"11762","DOI":"10.1038\/ncomms11762","article-title":"Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis","volume":"7","author":"M K Ruhland","year":"2016","journal-title":"Nat Commun"},{"issue":"08","key":"ref177","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41568-019-0156-2","article-title":"Unmasking senescence: context-dependent effects of SASP in cancer","volume":"19","author":"D V Faget","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"04","key":"ref178","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jhep.2016.05.030","article-title":"Senescence in chronic liver disease: is the future in aging?","volume":"65","author":"A D Aravinthan","year":"2016","journal-title":"J Hepatol"},{"issue":"04","key":"ref179","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2008.06.049","article-title":"Senescence of activated stellate cells limits liver fibrosis","volume":"134","author":"V Krizhanovsky","year":"2008","journal-title":"Cell"},{"issue":"02","key":"ref181","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jhep.2024.03.014","article-title":"Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis","volume":"81","author":"C N Yashaswini","year":"2024","journal-title":"J Hepatol"},{"issue":"7259","key":"ref182","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/4601085a","article-title":"Stem cells: the promises and perils of p53","volume":"460","author":"V Krizhanovsky","year":"2009","journal-title":"Nature"},{"issue":"05","key":"ref183","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1172\/JCI66369","article-title":"Hepatic stellate cells in liver development, regeneration, and cancer","volume":"123","author":"C Yin","year":"2013","journal-title":"J Clin Invest"},{"issue":"03","key":"ref184","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/cells9030671","article-title":"Immune clearance of senescent cells to combat ageing and chronic diseases","volume":"9","author":"P Song","year":"2020","journal-title":"Cells"},{"issue":"11","key":"ref185","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00535-019-01579-5","article-title":"Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma","volume":"54","author":"Y Mano","year":"2019","journal-title":"J Gastroenterol"},{"key":"ref186","doi-asserted-by":"crossref","first-page":"123678","DOI":"10.1016\/j.lfs.2025.123678","article-title":"Exploring the double-edged role of cellular senescence in chronic liver disease for new treatment approaches","volume":"373","author":"Y Yang","year":"2025","journal-title":"Life Sci"},{"issue":"04","key":"ref187","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/hep-2017-0011","article-title":"Cellular senescence associated immune responses in liver cancer","volume":"4","author":"T F Greten","year":"2017","journal-title":"Hepat Oncol"},{"issue":"02","key":"ref188","doi-asserted-by":"crossref","first-page":"jcs232470","DOI":"10.1242\/jcs.232470","article-title":"Senescent mesenchymal stem cells remodel extracellular matrix driving breast cancer cells to a more-invasive phenotype","volume":"133","author":"D Ghosh","year":"2020","journal-title":"J Cell Sci"},{"issue":"01","key":"ref189","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/cr.2010.183","article-title":"NF-\u03baB and STAT3\u2014key players in liver inflammation and cancer","volume":"21","author":"G He","year":"2011","journal-title":"Cell Res"},{"issue":"08","key":"ref190","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/ncb2811","article-title":"Transmitting senescence to the cell neighbourhood","volume":"15","author":"M Hoare","year":"2013","journal-title":"Nat Cell Biol"},{"issue":"01","key":"ref191","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2337\/db10-0892","article-title":"miR-200a prevents renal fibrogenesis through repression of TGF-\u03b22 expression","volume":"60","author":"B Wang","year":"2011","journal-title":"Diabetes"},{"issue":"7374","key":"ref192","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature10599","article-title":"Senescence surveillance of pre-malignant hepatocytes limits liver cancer development","volume":"479","author":"T W Kang","year":"2011","journal-title":"Nature"},{"issue":"08","key":"ref193","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41591-018-0092-9","article-title":"Senolytics improve physical function and increase lifespan in old age","volume":"24","author":"M Xu","year":"2018","journal-title":"Nat Med"},{"issue":"7814","key":"ref194","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","article-title":"Senolytic CAR T cells reverse senescence-associated pathologies","volume":"583","author":"C Amor","year":"2020","journal-title":"Nature"},{"issue":"09","key":"ref195","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/nm.4385","article-title":"Targeting cellular senescence prevents age-related bone loss in mice","volume":"23","author":"J N Farr","year":"2017","journal-title":"Nat Med"},{"key":"ref196","doi-asserted-by":"crossref","first-page":"13363","DOI":"10.1038\/ncomms13363","article-title":"A single heterochronic blood exchange reveals rapid inhibition of multiple tissues by old blood","volume":"7","author":"J Rebo","year":"2016","journal-title":"Nat Commun"},{"issue":"04","key":"ref197","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ccell.2016.09.003","article-title":"Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression","volume":"30","author":"T Eggert","year":"2016","journal-title":"Cancer Cell"},{"issue":"09","key":"ref198","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.tcb.2018.04.006","article-title":"Two-step senescence-focused cancer therapies","volume":"28","author":"C J Sieben","year":"2018","journal-title":"Trends Cell Biol"},{"issue":"02","key":"ref199","doi-asserted-by":"crossref","first-page":"200817","DOI":"10.1016\/j.omton.2024.200817","article-title":"Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma","volume":"32","author":"L Zhou","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"ref200","doi-asserted-by":"crossref","first-page":"116604","DOI":"10.1016\/j.bcp.2024.116604","article-title":"Targeting fibroblast activation protein with chimeric antigen receptor macrophages","volume":"230","author":"Y Mao","year":"2024","journal-title":"Biochem Pharmacol"},{"issue":"06","key":"ref201","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jhep.2024.01.034","article-title":"Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models","volume":"80","author":"H Dai","year":"2024","journal-title":"J Hepatol"},{"issue":"03","key":"ref202","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s43587-023-00560-5","article-title":"Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction","volume":"4","author":"C Amor","year":"2024","journal-title":"Nat Aging"},{"issue":"07","key":"ref203","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"T Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref204","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1038\/ncomms3823","article-title":"Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology","volume":"4","author":"I Mederacke","year":"2013","journal-title":"Nat Commun"},{"issue":"04","key":"ref205","first-page":"1453","article-title":"Origin of myofibroblasts in liver fibrosis in mice","volume":"124","author":"K Iwaisako","year":"2014","journal-title":"J Clin Invest"},{"issue":"03","key":"ref206","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"T Kisseleva","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"ref207","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41575-023-00821-z","article-title":"Friend or foe? The elusive role of hepatic stellate cells in liver cancer","volume":"20","author":"B Cogliati","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"05","key":"ref208","first-page":"1493","article-title":"Single-cell transcriptomics reveals zonation and injury-specific programs in hepatic stellate cells","volume":"157","author":"R Dobie","year":"2019","journal-title":"Gastroenterology"},{"issue":"7931","key":"ref209","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41586-022-05289-6","article-title":"Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis","volume":"610","author":"A Filliol","year":"2022","journal-title":"Nature"},{"issue":"10","key":"ref210","first-page":"632","article-title":"Fibroblasts in liver cancer: functions and therapeutic targets","volume":"20","author":"S Aff\u00f3","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41421-023-00529-z","article-title":"CD36+ cancer-associated fibroblasts create an immunosuppressive niche via MIF in hepatocellular carcinoma","volume":"9","author":"G-Q Zhu","year":"2023","journal-title":"Cell Discov"},{"issue":"05","key":"ref212","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1053\/j.gastro.2020.12.015","article-title":"Hepatic stellate cells in hepatocellular carcinoma promote tumor growth via growth differentiation factor 15 production","volume":"160","author":"Y Myojin","year":"2021","journal-title":"Gastroenterology"},{"key":"ref213","doi-asserted-by":"crossref","first-page":"1368898","DOI":"10.3389\/fimmu.2024.1368898","article-title":"Extracellular vesicles and cancer stemness in hepatocellular carcinoma\u2014is there a link?","volume":"15","author":"L Tian","year":"2024","journal-title":"Front Immunol"},{"issue":"06","key":"ref214","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3390\/cells9061331","article-title":"Cancer stem cell functions in hepatocellular carcinoma and comprehensive therapeutic strategies","volume":"9","author":"Y C Liu","year":"2020","journal-title":"Cells"},{"key":"ref215","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.canlet.2017.07.006","article-title":"Peri-tumor associated fibroblasts promote intrahepatic metastasis of hepatocellular carcinoma by recruiting cancer stem cells","volume":"404","author":"J Jiang","year":"2017","journal-title":"Cancer Lett"},{"issue":"01","key":"ref216","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.stem.2011.06.005","article-title":"CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation","volume":"9","author":"T K Lee","year":"2011","journal-title":"Cell Stem Cell"},{"issue":"04","key":"ref217","first-page":"340","article-title":"Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis","volume":"6","author":"I Ghanem","year":"2014","journal-title":"Am J Transl Res"},{"issue":"04","key":"ref218","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41419-022-04848-z","article-title":"Mechanism of cancer stemness maintenance in human liver cancer","volume":"13","author":"N Liang","year":"2022","journal-title":"Cell Death Dis"},{"issue":"03","key":"ref219","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3892\/or.2015.4126","article-title":"Hepatic stellate cells promote upregulation of epithelial cell adhesion molecule and epithelial-mesenchymal transition in hepatic cancer cells","volume":"34","author":"T Nagahara","year":"2015","journal-title":"Oncol Rep"},{"issue":"01","key":"ref220","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1038\/s41598-017-01177-6","article-title":"Activated hepatic stellate cells secrete periostin to induce stem cell-like phenotype of residual hepatocellular carcinoma cells after heat treatment","volume":"7","author":"R Zhang","year":"2017","journal-title":"Sci Rep"},{"issue":"01","key":"ref221","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13046-019-1163-6","article-title":"Resolvin D1 prevents epithelial-mesenchymal transition and reduces the stemness features of hepatocellular carcinoma by inhibiting paracrine of cancer-associated fibroblast-derived COMP","volume":"38","author":"L Sun","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"22","key":"ref222","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1158\/0008-5472.CAN-20-4226","article-title":"FSTL1 secreted by activated fibroblasts promotes hepatocellular carcinoma metastasis and stemness","volume":"81","author":"J J Loh","year":"2021","journal-title":"Cancer Res"},{"issue":"01","key":"ref223","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41392-024-01887-0","article-title":"Semaphorin 3C (Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression","volume":"9","author":"H Peng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"01","key":"ref224","doi-asserted-by":"crossref","first-page":"e2929","DOI":"10.1002\/iub.2929","article-title":"KGF secreted from HSCs activates PAK4\/BMI1, promotes HCC stemness through PI3K\/AKT pathway","volume":"77","author":"Q Li","year":"2025","journal-title":"IUBMB Life"},{"issue":"07","key":"ref225","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3390\/cells8070727","article-title":"Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis","volume":"8","author":"L M Doyle","year":"2019","journal-title":"Cells"},{"issue":"06","key":"ref226","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jhep.2020.07.014","article-title":"Extracellular vesicles as biomarkers in liver diseases: a clinician's point of view","volume":"73","author":"S Thietart","year":"2020","journal-title":"J Hepatol"},{"issue":"01","key":"ref227","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s40364-024-00669-8","article-title":"Novel insights into the role of immunomodulatory extracellular vesicles in the pathogenesis of liver fibrosis","volume":"12","author":"J Li","year":"2024","journal-title":"Biomark Res"},{"issue":"01","key":"ref228","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13046-025-03380-0","article-title":"Reduction of alternative polarization of macrophages by short-term activated hepatic stellate cell-derived small extracellular vesicles","volume":"44","author":"Y Sun","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"ref229","doi-asserted-by":"crossref","first-page":"1489679","DOI":"10.3389\/fimmu.2024.1489679","article-title":"Activated hepatic stellate cell-derived small extracellular vesicles facilitate M2 macrophage polarization and hepatoma progression via miR-27a-3p","volume":"15","author":"Y Sun","year":"2024","journal-title":"Front Immunol"},{"issue":"11","key":"ref230","first-page":"5254","article-title":"PRDM16 from hepatic stellate cells-derived extracellular vesicles promotes hepatocellular carcinoma progression","volume":"13","author":"C Sun","year":"2023","journal-title":"Am J Cancer Res"},{"issue":"06","key":"ref231","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.7150\/ijbs.66184","article-title":"Exosome-depleted MiR-148a-3p derived from hepatic stellate cells promotes tumor progression via ITGA5\/PI3K\/Akt axis in hepatocellular carcinoma","volume":"18","author":"X Zhang","year":"2022","journal-title":"Int J Biol Sci"},{"issue":"01","key":"ref232","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/hep.30607","article-title":"Endoplasmic reticulum stress causes liver cancer cells to release exosomal miR-23a-3p and up-regulate programmed death ligand 1 expression in macrophages","volume":"70","author":"J Liu","year":"2019","journal-title":"Hepatology"},{"issue":"02","key":"ref233","doi-asserted-by":"crossref","first-page":"e2404089","DOI":"10.1002\/advs.202404089","article-title":"Cancer cell-derived exosomal miR-500a-3p modulates hepatic stellate cell activation and the immunosuppressive microenvironment","volume":"12","author":"Y Zhang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"issue":"04","key":"ref234","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41419-021-03494-1","article-title":"MIRLET7BHG promotes hepatocellular carcinoma progression by activating hepatic stellate cells through exosomal SMO to trigger Hedgehog pathway","volume":"12","author":"Y Xia","year":"2021","journal-title":"Cell Death Dis"},{"issue":"01","key":"ref235","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41467-017-02583-0","article-title":"Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer","volume":"9","author":"T Fang","year":"2018","journal-title":"Nat Commun"},{"issue":"10","key":"ref236","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/s42255-022-00642-5","article-title":"HK1 from hepatic stellate cell-derived extracellular vesicles promotes progression of hepatocellular carcinoma","volume":"4","author":"Q T Chen","year":"2022","journal-title":"Nat Metab"},{"issue":"01","key":"ref237","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/hep.29803","article-title":"Hepatic stellate cell-derived platelet-derived growth factor receptor-alpha-enriched extracellular vesicles promote liver fibrosis in mice through SHP2","volume":"68","author":"E Kostallari","year":"2018","journal-title":"Hepatology"},{"issue":"8080","key":"ref238","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-025-09297-0","article-title":"ACLY inhibition promotes tumour immunity and suppresses liver cancer","volume":"645","author":"J Gautam","year":"2025","journal-title":"Nature"},{"issue":"01","key":"ref239","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/s41467-025-56024-4","article-title":"Trajectory analysis of hepatic stellate cell differentiation reveals metabolic regulation of cell commitment and fibrosis","volume":"16","author":"R A Mart\u00ednez Garc\u00eda de la Torre","year":"2025","journal-title":"Nat Commun"},{"issue":"06","key":"ref240","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","article-title":"Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia","volume":"34","author":"M R Morrow","year":"2022","journal-title":"Cell Metab"},{"issue":"01","key":"ref241","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cmet.2025.11.015","article-title":"Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH","volume":"38","author":"Pastena Di","year":"2026","journal-title":"Cell Metabolism"},{"issue":"09","key":"ref242","doi-asserted-by":"crossref","first-page":"101193","DOI":"10.1016\/j.xcrm.2023.101193","article-title":"Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice","volume":"4","author":"E M Desjardins","year":"2023","journal-title":"Cell Rep Med"},{"key":"ref243","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/s42255-022-00642-5","article-title":"Hepatic stellate cell\u2013derived extracellular vesicles deliver hexokinase-1 to hepatocellular carcinoma to drive glycolysis and metastasis","volume":"4","author":"Q-T Chen","year":"2022","journal-title":"Nat Metab"},{"issue":"02","key":"ref244","doi-asserted-by":"crossref","first-page":"113947","DOI":"10.1016\/j.yexcr.2024.113947","article-title":"Cancer-associated fibroblasts contributed to hepatocellular carcinoma recurrence and metastasis via CD36-mediated fatty-acid metabolic reprogramming","volume":"435","author":"H Wang","year":"2024","journal-title":"Exp Cell Res"},{"issue":"05","key":"ref245","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.3390\/ijms21051606","article-title":"Monocarboxylate transporter 1 (MCT1) in liver pathology","volume":"21","author":"M Dro\u017adzik","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7617","key":"ref246","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature19084","article-title":"Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion","volume":"536","author":"C M Sousa","year":"2016","journal-title":"Nature"},{"issue":"04","key":"ref247","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1053\/j.gastro.2011.12.044","article-title":"Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues","volume":"142","author":"V Hern\u00e1ndez-Gea","year":"2012","journal-title":"Gastroenterology"},{"key":"ref248","doi-asserted-by":"crossref","first-page":"730176","DOI":"10.3389\/fcell.2021.730176","article-title":"Liver fibrosis: therapeutic targets and advances in drug therapy","volume":"9","author":"Z Tan","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"03","key":"ref249","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3350\/cmh.2020.0187","article-title":"Anti-fibrotic treatments for chronic liver diseases: the present and the future","volume":"27","author":"N Odagiri","year":"2021","journal-title":"Clin Mol Hepatol"},{"issue":"03","key":"ref250","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","volume":"72","author":"V Ratziu","year":"2020","journal-title":"Hepatology"},{"issue":"01","key":"ref251","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cgh.2023.04.003","article-title":"Cenicriviroc lacked efficacy to treat liver fibrosis in adults with nonalcoholic steatohepatitis: results from the AURORA phase 3 trial","volume":"22","author":"Q M Anstee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"02","key":"ref252","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.30237","article-title":"Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease","volume":"69","author":"A J Muir","year":"2019","journal-title":"Hepatology"},{"issue":"06","key":"ref253","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis (MAESTRO-NASH)","volume":"390","author":"S A Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"04","key":"ref254","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"J M Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"ref255","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma (REFLECT)","volume":"391","author":"M Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref256","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib (RESORCE)","volume":"389","author":"J Bruix","year":"2017","journal-title":"Lancet"},{"issue":"04","key":"ref257","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"A L Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"12","key":"ref258","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signalling as a driver event in hepatocellular carcinoma","volume":"9","author":"R D Kim","year":"2019","journal-title":"Cancer Discov"},{"key":"ref259","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ebiom.2018.12.052","article-title":"Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study","volume":"40","author":"J N Justice","year":"2019","journal-title":"EBioMedicine"},{"key":"ref260","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","article-title":"Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease","volume":"47","author":"L J Hickson","year":"2019","journal-title":"EBioMedicine"},{"issue":"12","key":"ref261","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.3390\/ijms21124255","article-title":"Extracellular vesicles: a therapeutic option for liver fibrosis","volume":"21","author":"S Bruno","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"01","key":"ref262","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12967-024-05282-9","article-title":"Mesenchymal stromal cell-derived extracellular vesicles therapy openings new translational challenges in immunomodulating acute liver inflammation","volume":"22","author":"A Sitbon","year":"2024","journal-title":"J Transl Med"},{"issue":"05","key":"ref263","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores","volume":"157","author":"G N Ioannou","year":"2019","journal-title":"Gastroenterology"},{"issue":"19","key":"ref264","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa0804525","article-title":"Gene expression in fixed tissues and outcome in hepatocellular carcinoma","volume":"359","author":"Y Hoshida","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2779-4937.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:31:16Z","timestamp":1777674676000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2779-4937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":263,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2026,5,1]]},"published-print":{"date-parts":[[2026,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2779-4937","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,30]]},"published":{"date-parts":[[2025,12,30]]}}}